ELAN

Elanco Animal Health Inc. - 10-Q Summary (Q3 2025)

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Elanco Animal Health Inc. operates as a single segment global leader in animal health, serving pet health (dogs and cats) and farm animal (cattle, poultry, swine) markets. The company recently divested its aqua business in July 2024 and acquired a manufacturing facility in Speke, U.K., in November 2024 to mitigate supply disruptions.

Key Financial Metrics

Note: Q3 2024 results included a $640 million pre-tax gain on the divestiture of the aqua business, which significantly inflated prior-year profitability.

Material Changes vs. Prior Period

• Revenue Growth: Q3 2025 revenue increased 10% year-over-year, driven by volume growth in Pet Health (led by new products Credelio Quattro and Zenrelia) and Farm Animal (cattle and poultry). Pricing was flat to slightly negative in Q3 but positive for the nine-month period.
• Profitability Decline: Net income turned to a loss of $34 million in Q3 2025 compared to $364 million in Q3 2024. This variance is primarily due to the absence of the $640 million one-time gain on the aqua divestiture recorded in the prior year.
• Special Charges: Asset impairment, restructuring, and other special charges were $25 million in Q3 2025, up from $17 million in Q3 2024. This includes $16 million related to the indefinite suspension of two early-stage capital projects.
• Debt Reduction: Interest expense decreased 10% in Q3 and 26% for the nine months ended September 30, 2025, due to lower average outstanding debt balances following paydowns.

Guidance, Outlook, and Risks

• Debt Refinancing (Subsequent Event): On October 31, 2025, Elanco refinanced its Term Loan B due 2027 ($2.1 billion) with three new facilities totaling $2.1 billion in gross proceeds. This extends the maturity profile and is expected to lower future interest costs. The weighted-average effective interest rate decreased to 5.77% post-refinancing.
• Sale of Future Revenue: In May 2025, the company sold future royalty rights related to XDEMVY to Blackstone for $295 million. While recorded as a liability, the proceeds were used to repay debt. The company continues to recognize the royalties as revenue under GAAP.
• Regulatory & Product Pipeline: Key products include Bovaer (methane reduction), Zenrelia (atopic dermatitis in dogs), and Credelio Quattro (parasite control). Regulatory approvals have been received in multiple markets.
• Risks:
  • Trade Policy: New tariffs and trade policies may impact international sales, though pharmaceutical products were largely exempt from early 2025 U.S. tariffs.
  • Sustainability Incentives: Adoption of sustainability products like Bovaer may be tempered by the freezing or rescinding of U.S. government incentives.
  • Legal Proceedings: Ongoing securities class actions and derivative suits regarding product safety and labeling (Zenrelia, Credelio Quattro) and antitrust claims (Tevra Brands) remain active.

Investor Verification Checklist

• Debt Covenant Compliance: Verify continued compliance with leverage and interest coverage covenants following the October 2025 refinancing.
• Product Launch Performance: Monitor sales velocity of new products (Zenrelia, Credelio Quattro, AdTab) to ensure they offset the loss of aqua business revenue.
• Legal Exposure: Track developments in the Barpar securities class action and Tevra antitrust litigation for potential financial impact.
• Working Capital Trends: Review accounts receivable and inventory levels, particularly given the $116 million receivable from a single customer representing 12% of revenue.
• FX Sensitivity: Assess the impact of foreign currency fluctuations, as approximately 51% of revenue is denominated in foreign currencies.